Ligand Pharmaceuticals (LGND) Common Equity (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Common Equity of $997.3 million for Q1 2026, down 1.96% sequentially from $1.0 billion in Q4 2025, and up 25.36% YoY from $795.6 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Common Equity (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $997.3 million in Q1 2026.
- Quarterly Common Equity rose 25.36% year-over-year to $997.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $997.3 million (up 25.36% YoY) and the FY2025 annual result came in at $1.0 billion, up 22.49% from the prior year.
- Common Equity eased to $997.3 million in Q1 2026 per LGND's latest filing, from $1.0 billion in the prior quarter.
- Over five years, Common Equity peaked at $1.0 billion in Q4 2025 and troughed at $597.5 million in Q4 2022.
- A 5-year average of $795.9 million and a median of $802.4 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity decreased 27.24% in 2022, then gained 25.94% in 2024.
- Over 5 years, Common Equity stood at $597.5 million in 2022, then increased by 17.31% to $700.9 million in 2023, then gained by 18.48% to $830.4 million in 2024, then advanced by 22.49% to $1.0 billion in 2025, then dropped by 1.96% to $997.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $997.3 million, $1.0 billion, and $950.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 967.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 967.52 Mn |
| Mar 31, 2026 | 997.32 Mn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 950.17 Mn |
| Jun 30, 2025 | 827.31 Mn |
| Mar 31, 2025 | 795.59 Mn |
| Dec 31, 2024 | 830.44 Mn |
| Sep 30, 2024 | 841.18 Mn |
| Jun 30, 2024 | 775.20 Mn |
| Mar 31, 2024 | 806.52 Mn |
| Dec 31, 2023 | 700.91 Mn |
| Sep 30, 2023 | 667.90 Mn |
| Jun 30, 2023 | 664.89 Mn |
| Mar 31, 2023 | 646.32 Mn |
| Dec 31, 2022 | 597.49 Mn |
| Sep 30, 2022 | 816.30 Mn |
| Jun 30, 2022 | 802.37 Mn |
| Mar 31, 2022 | 793.19 Mn |
| Dec 31, 2021 | 821.16 Mn |
| Sep 30, 2021 | 812.07 Mn |